Pharmaceutical Business Development and Licensing (BD&L)
46 views | +0 today
Follow
 
Scooped by Rachit Singla
onto Pharmaceutical Business Development and Licensing (BD&L)
Scoop.it!

Benzinga's Weekend M&A Chatter - Benzinga

Benzinga's Weekend M&A Chatter - Benzinga | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday Decmeber 5 throught Sunday December 7, 2014:
Merck in Talks to Acquire Cubist for ~$...
more...
No comment yet.
Your new post is loading...
Your new post is loading...
Scooped by Rachit Singla
Scoop.it!

Tax inversion anyone? A year in M&A - CNBC

Tax inversion anyone? A year in M&A - CNBC | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Mergers and acquisitions broke a seven-year losing streak in 2014, with $3.48 trillion worth of deals. CNBC looks at some of the year's highlights.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Big Data & Analytics for Pharma Summit, Philadelphia

Big Data & Analytics for Pharma Summit, Philadelphia | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The Big Data & Analytics for Pharma Summit is a must attend event for those involved within the field.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

2015 Life Sciences Outlook | Deloitte US | Life Sciences & Health Care

2015 Life Sciences Outlook | Deloitte US | Life Sciences & Health Care | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
What factors are likely to shape the life sciences industry in the coming year and beyond? Read Deloitte's 2015 Life Sciences Outlook.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Novartis and Glaxo Deal Reshapes Pharma Industry

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plum...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Strong Q4 Activity Makes 2014 The Best Year For M&A Since Downturn - Forbes

Strong Q4 Activity Makes 2014 The Best Year For M&A Since Downturn - Forbes | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Deals worth almost $3.5 trillion were announced over the year – a good 47% improvement over the figure for 2013. The total number of announced deals also jumped from 36,800 in 2013 to 40,462 in 2014.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

23andMe Gives Pfizer Access To Its Genome Database

23andMe Gives Pfizer Access To Its Genome Database | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The partnership sounds like a win-winso long as 23andMe's client data stays anonymous.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Life Sciences Group Of the Year: Skadden - Law360 (subscription)

Life Sciences Group Of the Year: Skadden - Law360 (subscription) | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
In a year bursting with merger deals in the life sciences sector, Skadden Arps Slate Meagher & Flom LLP guided Merck KGaA through one of the biggest — a $17 billion acquisition of Sigma-Aldrich Corp., securing the firm a place on Law360's list of...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Roche seals licensing deal for antibiotic-boosting drug to battle superbugs

Roche seals licensing deal for antibiotic-boosting drug to battle superbugs | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
ZURICH (Reuters) - Roche has boosted its efforts to tackle antibiotic resistance, striking a deal worth up to $750 million with Japan's Meiji Seika Pharma and Canada's Fedora for a drug that can restore...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

The Changing Landscape of the Biotech Pharma Deal

Biotech and Pharma industry experts converse on deal making trends. Learn how you can position your technology and/or company for success in the current envi...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Life Sciences Merger and Acquisitions in Q4 2014 - Life Sciences Connect

Life Sciences Merger and Acquisitions in Q4 2014 - Life Sciences Connect | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The M&A activity in the Life Sciences sector in Q4 2014 ended on a high note giving a boost to the total deal activity in the year 2014.
Rachit Singla's insight:

Life Sciences industry registered strong M&A activity in Q4 2014, giving strong momentum to 2015.

more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet - FiercePharma

With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet - FiercePharma | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
With a months-long hostile pursuit from Valeant and failed talks to buy North Carolina's Salix, Allergan had already been on an M&A roller coaster this year before finally agreeing to sell itself to Actavis last month.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

KKR to acquire minority stake in Arbor Pharmaceuticals

KKR to acquire minority stake in Arbor Pharmaceuticals | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
New York-based private equity firm KKR has agreed to acquire a significant minority stake in specialty drugmaker Arbor Pharmaceuticals, in a bid to help drive continued growth
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Countries sign agreement to curb corporate tax evasion

Countries sign agreement to curb corporate tax evasion | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Several governments are trying to change rules that allow corporations and individuals to avoid paying taxes.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Big pharma deals are a way to return more to shareholders - Kelly

BIG PHARMA DEALS ARE A WAY TO RETURN MORE TO SHAREHOLDERS - KELLY Pfizer disclosed its $100bln pursuit of Britain's astrazeneca, while GSK ...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Notable Life Sciences Merger & Acquisitions in Q1 2015 | Life Sciences Connect

Notable Life Sciences Merger & Acquisitions in Q1 2015 | Life Sciences Connect | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Rachit Singla's insight:

Hyperactivity in life sciences M&A registered in Q1 2015, with $71.7 billions announced in deal values. 

more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

What Will Pharma Do When There Are No More Mega Mergers?

What Will Pharma Do When There Are No More Mega Mergers? | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Mega-mergers have been a fact of life in the pharmaceutical industry for decades now, according to a McKinsey article by Myoung Cha and Theresa Loriman earlier this year, “Why pharma megamergers work.” Their report refutes a common belief that such...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples – Human Longevity, Inc.

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples – Human Longevity, Inc. | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
RT @genentech: #Partnering with @humanlongevity could yield powerful new insights into #PersonalizedMedicine http://t.co/MyA9eNC6pK
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

CTI Life Sciences successfully raises new C$ 134 Million venture capital fund - FierceBiotech

CTI Life Sciences successfully raises new C$ 134 Million venture capital fund - FierceBiotech | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
MONTREAL, Jan. 15, 2015 /PRNewswire/ - CTI Life Sciences announced today the first closing of its second venture capital fund ("CTI II"), with C$134 million of capital now available for...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Why Indian startups like Bugworks, Vitas Pharma have entered the field of drug discovery - The Economic Times

Why Indian startups like Bugworks, Vitas Pharma have entered the field of drug discovery - The Economic Times | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The WHO’s first report on the global state of antibiotic-resistant bacteria recently warned that the world is entering a “postantibiotic era”, in which even the most powerful antibiotics available are becoming ineffective against infections so...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Torrent inks exclusive biosimilars licensing deal with private Indian drug firm - Generic Pharma Litigator

Torrent inks exclusive biosimilars licensing deal with private Indian drug firm - Generic Pharma Litigator | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
Torrent inks exclusive biosimilars licensing deal with private Indian drug firm - http://t.co/aMlhpIj9dK http://t.co/27k80oTgOH
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Australian life sciences and tropical medicine delegation promote their ... - Financial Express

Australian life sciences and tropical medicine delegation promote their ... - Financial Express | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
The delegation is here to participate in Australia Business Week in India
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

2015 Pharma Predictions: Drug Deals | CNBC

CNBC's Meg Tirrell looks at ways to make money in the pharma and biotech space next year. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC About CNBC: From '...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

5 Keys to Partnering for Succession - WealthManagement.com

Succession conversations typically focus on two strategies: cultivating a successor from within or aligning with another advisor/owner outside of the firm. An alternative approach—and one that’s worth considering—is merging your firm with another.
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

Avanir Pharmaceuticals Acquired For $3.5 Billion | socalTECH.com

Aliso Viejo-based Avanir Pharmaceuticals said today that it has entered into a definitive agreement to be acquired by Japanese company Otsuka Pharmaceutical Co., Ltd., in a deal worth approximately $3...
more...
No comment yet.
Scooped by Rachit Singla
Scoop.it!

With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet

With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet | Pharmaceutical Business Development and Licensing (BD&L) | Scoop.it
With a months-long hostile pursuit from Valeant and failed talks to buy North Carolina's Salix, Allergan had already been on an M&A roller coaster this year before finally agreeing to sell itself to Actavis last month.
more...
No comment yet.